Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

MYSTERIOUS: Here s what to expect from incyte s next earnings report - What They Never Told You

With a market cap of $19 billion, Incyte Corporation (INCY) is a Delaware–based biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies, primarily in oncology and inflammatory diseases. The company specializes in small-molecule drugs that modulate specific biological pathways, particularly those involved in cancer and immune system disorders. 

The company is set to unveil its fiscal Q1 2026 results before the market opens on Tuesday, Apr. 28. Ahead of this event, analysts expect INCY to report a profit of $1.21 per share, up 36% from $0.89 per share in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarters while missing on another occasion.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.